FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Prescription drugs, Inc. (NASDAQ: MIRM) at this time introduced that it’ll host an investor name on Monday, June 17 at 8:30 a.m. ET to share interim evaluation outcomes from the Volixibat VANTAGE Section 2b examine in major biliary cholangitis (PBC) and the Volixibat VISTAS Section 2b examine in major sclerosing cholangitis (PSC).
Convention name particulars:
Monday June 17, 2024
8:30 a.m. ET / 5:30 a.m. PT
Dial-in:
U.S./Toll-Free: +1 833 470 1428
Worldwide: +1 404 975 4839
Passcode: 205511
You might also entry the decision through webcast by visiting the Occasions & Displays part on Mirum’s web site. A replay of this webcast will likely be obtainable for 30 days.
About Mirum Prescription drugs (NASDAQ:), Inc.
Mirum Prescription drugs, Inc. is a biopharmaceutical firm devoted to remodeling the therapy of uncommon illnesses affecting youngsters and adults. Mirum has three authorised drugs: LIVMARLI ® (maralixibat) oral answer, CHOLBAM ® (cholic acid) capsules, and CHENODAL ® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is authorised for the therapy of two uncommon liver illnesses affecting youngsters and adults. It’s authorised for the therapy of cholestatic pruritus in sufferers with Alagille syndrome within the U.S. (three months and older), in Europe (two months and older), and in different areas globally. It’s also authorised within the U.S. in cholestatic pruritus in PFIC sufferers 5 years of age and older. LIVMARLI has obtained constructive opinion by CHMP in Europe for the therapy of PFIC in sufferers three months of age and older. A call by the European Fee is predicted by the third quarter of 2024. CHOLBAM is FDA-approved for the therapy of bile acid synthesis problems as a result of single enzyme deficiencies and adjunctive therapy of peroxisomal problems in sufferers who present indicators or signs or liver illness. CHENODAL has obtained medical necessity recognition by the FDA to deal with sufferers with cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline contains two investigational remedies for debilitating liver illnesses. Volixibat, an IBAT inhibitor, is being evaluated in two probably registrational research together with the Section 2b VISTAS examine for major sclerosing cholangitis and Section 2b VANTAGE examine for major biliary cholangitis. Lastly, CHENODAL has been evaluated in a Section 3 medical examine, RESTORE, to deal with sufferers with CTX, with constructive topline outcomes reported in 2023.
To be taught extra about Mirum, go to mirumpharma.com and comply with Mirum on Fb (NASDAQ:), LinkedIn, Instagram and Twitter (X).
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240616032628/en/
Buyers:
Andrew McKibben
ir@mirumpharma.com
Media:
Erin Murphy
media@mirumpharma.com
Supply: Mirum Prescription drugs, Inc.
